Epidemiological and interventional studies have demonstrated the existence of an inverse relationship between HDL cholesterol (HDL-C) 5 concentration and coronary heart disease (1-3). However, the clinical efficacy of increasing plasma HDL-C concentration to reduce cardiovascular risk has been difficult to prove. Recently published outcome trials involving the addition of high-dose niacin or inhibitors of the cholesteryl ester transfer protein to standard LDL cholesterol (LDL-C) reduction therapy failed to report clinical benefits, despite a significant increase in HDL-C concentration (4) (5) (6) (7) . Furthermore, genetic variants related to high HDL-C concentration are not consistently associated with improved cardiovascular outcomes (8) . These findings have highlighted the limitations of using HDL-C concentration for assessing cardiovascular risk and the response to therapies that target HDL-C.
The notion of HDL functionality has been circulating in this field of research for years and is based on the known heterogeneity in lipid content, protein cargo, and size of HDL particles. HDL has been shown to have a variety of functions that may contribute to its cardiovascular-protective effects, including reverse cholesterol transport and antiinflammatory and antioxidative properties (9, 10) . Although the relative mechanistic contributions of HDL-mediated atheroprotection remain unclear, a key function of HDL is thought to be the efflux of cholesterol from macrophages in the arterial wall. Animal and clinical studies have suggested that cholesterol flux through this pathway is a better predictor of the atherosclerotic impact of various genetic and pharmacological perturbations than is circulating HDL-C concentration (11, 12) . In the conventional procedures that are used to measure efflux capacity, macrophages are incubated with radiolabeled cholesterol and are then exposed to the HDL fraction from individual subjects, thus allowing the quantification of the resulting cholesterol efflux from the cells (13) . Although this method of measuring cholesterol efflux has provided large amounts of data on the efficiency of various extracellular acceptors and on different efflux pathways, the protocol, which calls for radiolabeled cholesterol and cultured cells, does not lend itself to the development of a high-throughput assay that can efficiently screen large numbers of specimens, such as human serum or plasma samples, in a clinical setting.
In the present study, we hypothesized that the efficiency of HDL-induced cholesterol efflux from macrophages depends mainly on the capacity of HDL to uptake cholesterol. To test this hypothesis, we constructed a cell-free assay system to evaluate cholesterol uptake capacity using the fluorescently labeled reagent boron dipyrromethene difluoride (BODIPY) linked to cholesterol (14) and a specific antibody against apolipoprotein A1 (apoA1), which is the most abundant protein component of HDL. We analyzed the performance of this assay system by calculating its dynamic range, sensitivity, and reproducibility. We also sought to investigate the feasibility of cholesterol uptake capacity for coronary risk stratification. serum, StartingBlock (PBS) Blocking Buffer, BODIPY ® FL fluorescent dye, Pierce Western Blotting Substrate Plus, and the SuperSignal ELISA Pico Chemiluminescence Substrate were purchased from Thermo Scientific. BSA was purchased from Proliant. BODIPY-cholesterol was purchased from Avanti Polar Lipids. The anti-apoA1 antibody (clone 1C5) was purchased from Sanbio B.V. The antiapoA1 antiserum was purchased from Nittobo Medical. The anti-nitrotyrosine antibody was purchased from Cell Signaling Technology. Recombinant myeloperoxidase (MPO) was purchased from R&D Systems. Horseradish peroxidase (HRP)-conjugated immunoglobulins were purchased from Dako. The apoA2 antibody (clone 4F3) was purchased from Abnova. The apoE antibody (clone E6D7) was purchased from GeneTex. Stock solutions of BODIPY-cholesterol and BODIPY-FL were prepared by dissolving each reagent in dimethyl sulfoxide at 0.5 mmol/L, and the solutions were stored at −20°C. The stock solution of liposome, as a regular component of the reaction buffer, was made from 25 mmol/L hydrogenated soy phosphatidylcholine, 12.5 mmol/L 1,2-dimyristoylsn-glycero-3-phosphoglycerol, and 12.5 mmol/L cholesterol. To prepare this liposome, we dissolved Presome ™ from Nihon Pure Chemical in PBS and generated a uniform population of liposomes using membranes with a pore size of 100 nm.
Preparation of the HDL fraction from human serum
Serum samples were thawed on ice and incubated with the same volume of 22% polyethylene glycol (PEG) 4000, to remove apoB-containing lipoproteins. In brief, each serum sample was mixed with PEG solution and kept at room temperature for 20 min. The samples were then centrifuged at 860g for 15 min, to precipitate all apoB-containing lipoproteins, and the supernatant was collected as the HDL fraction (apoB-depleted serum). Aliquots of the apoB-depleted serum were stored at −80°C. The lipoprotein-deficient serum was prepared from apoB-depleted serum using the RLPcholesterol JIMRO II kit (Otsuka Pharmaceutical) according to the manufacturer's instructions.
Cholesterol uptake assay and apoA1 sandwich ELISA One hundred microliters of 10 μg/mL of the antiapoA1 antibody (clone 1C5) in 50 mmol/L Tris-HCl, pH 7.5, was added to the wells of a 96-well blackbottom microplate, and the plate was incubated overnight. One microliter of the apoB-depleted serum sample, which was adjusted to its apoA1 concentration of 5 μg/mL in PBS containing 2% BSA, unless otherwise indicated, was incubated with 100 μL of 5 μmol/L BODIPY-cholesterol in PBS containing 2% BSA and 1.1% liposome stock solution (for reduction of nonspecific binding of BODIPYcholesterol to microtubes and microplates, see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www. jalm.org/content/vol2/issue1) at 37°C for 2 h in a tube shaker at 800 rpm. After the microtubes were placed on ice for 10 min, ice-cold hydrogen peroxide (H 2 O 2 ), sodium nitrite, and diethylenetriaminepentaacetic acid (DTPA) were added to the mixture (final concentrations 1 mol/L, 200 μmol/L, and 100 μmol/L, respectively), which was incubated at 37°C for 1 h at 800 rpm to minimize the recognition bias of the anti-apoA1 antibody. After washing the wells with PBS 3 times, PBS containing 2% BSA was added to each well of the plate, and the plate was incubated at 25°C at 500 rpm on a plate shaker for 3 h. The blocking buffer was removed from the wells, 100 μL of the apoB-depleted serum mixture was transferred into the wells, and the plate was incubated at 25°C for 1 h at 600 rpm. After the wells were washed with 200 μL PBS 5 times, 100 μL of 20 mmol/L cyclodextrin in PBS was added to the wells to enhance the fluorescence signal derived from BODIPY-cholesterol (Fig. 2 in the online Data Supplement), and the plate was incubated at 25°C for 1 h at 600 rpm. The fluorescence intensity was measured at 535 nm with excitation at 485 nm on an Infinite 200 Pro microplate reader (Tecan).
To quantify the apoA1 captured on the microplate, the cyclodextrin solution was removed and the wells were washed 3 times with 200 μL PBS containing 0.01% CHAPS. One hundred microliters of the anti-apoA1 antiserum diluted with StartingBlock buffer by 1000 times was added to the wells, and the plate was incubated at 25°C for 1 h at 600 rpm. The wells were washed 3 times, 100 μL of HRP-conjugated antigoat immunoglobulin diluted with StartingBlock buffer by 1000 times was added to the wells, and the plate was incubated at 25°C for 1 h at 600 rpm. The wells were washed 5 times, 100 μL SuperSignal ELISA Pico reagent was added to the wells, and the plate was incubated at 25°C for 2 min at 600 rpm. Chemiluminescence was measured on the microplate reader.
apoA1 concentrations in apoB-depleted serum were measured using a commercially available kit (Nittobo Medical, N-Assay Apo AI-H) and an automatic clinical analyzer (Hitachi, 7180).
Uptake capacity was calculated by subtracting the background signal obtained for PBS from the uptake detected for apoB-depleted serum samples, divided by apoA1 signals for captureefficiency adjustment. In the case of multiplate measurements, a calibration curve was generated using serial dilutions of recombinant apoA1 for each microplate, followed by standardization of the fluorescence signal intensities derived from apoB-depleted serum samples and adjustment for captured apoA1 signals. QC sample was prepared from pooled apoB-depleted serum.
MPO-induced oxidation of HDL and apoA1
Reactions were performed at 37°C for 1 h in PBS with 100 μmol/L DTPA, pH 7.4, containing recombinant apoA1-or apoB-depleted serum (0.5 μg/mL apoA1) supplemented with 100 nmol/L MPO, 100 μmol/L nitrite, and 20 or 40 μmol/L H 2 O 2 . The reaction was initiated by adding the oxidant and terminated by adding 2 mmol/L methionine.
Immunoblot analysis
Recombinant apoA1-and apoB-depleted serum samples were boiled in SDS-PAGE loading buffer (2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.002% bromophenol blue, 62.5 mmol/L Tris-HCl, pH 6.8), resolved using SDS-PAGE, and transferred onto a polyvinylidene difluoride membrane. The proteins were detected using appropriate primary and HRP-conjugated secondary antibodies, followed by Western blotting substrate.
Cholesterol efflux assay
Macrophage-specific efflux capacity was measured using BODIPY-cholesterol by a method reported previously with modifications (15) . J774 mouse macrophages were dispensed into a 48-well plate at 7 × 10 4 cells per well. After 24 h, the cells were incubated for 2.5 h with 8 μmol/L BODIPY-cholesterol and in DMEM with 10% fetal bovine serum and 10 mmol/L cyclodextrin. After washing with phenol red-free DMEM, the BODIPYcholesterol-labeled cells were incubated with 0.5% apoB-depleted serum in phenol red-free DMEM for 24 h at 37°C. The resulting quantity of BODIPY-cholesterol in the medium was measured on a microplate reader, and the efflux capacity was calculated as the amount of effluxed BODIPYcholesterol expressed as a fraction of the initial cell content of BODIPY-cholesterol. The efflux capacity was divided by the amount of apoA1 in apoBdepleted serum, for an assessment of the relationship with uptake capacity, because the uptake capacity was measured at a constant level of apoA1 in apoB-depleted serum (efflux capacity/apoBdepleted serum apoA1).
Subjects
The serum samples used for the construction and evaluation of the cholesterol uptake assay were purchased from Tokyo Future Style. To assess the relationship between cholesterol uptake capacity and the recurrence of coronary artery disease (CAD), we enrolled 230 consecutive patients who had previously undergone successful percutaneous coronary intervention or coronary artery bypass grafting and who had been hospitalized for the purpose of CAG (coronary angiography) from April 2011 to July 2015 because of follow-up or stable angina or inducible ischemia.
The participants who required coronary revascularization because of restenosis of the original target lesion and/or occurrence of other nontargeted coronary atherosclerotic lesions were classified as having CAD recurrence. The exclusion criteria were emergency admission, acute coronary syndrome, heart failure, renal failure (creatinine >3.0 mg/dL), or a history of cancer in the past 5 years. All subjects signed an informed consent form, and all protocols were approved by the Kobe University Institutional Review Board.
Statistical analyses
This study was designed to have an 80% power to detect a 67% reduction in the hazard of cardiac disease recurrence at an α level of 0.05 in a 2-sided test based on the Schoenfeld method and observational study results (16, 17) . To achieve this level of power, at least 34 primary endpoints had to occur with a range of 16 -50 cases based on the sensitivity analyses of hazard ratio and 25% recurrence rate from our institute data. All data are expressed as the mean (SD) unless otherwise specified. The P values for the comparisons between 2 groups were assessed using Student t-test or the Mann-Whitney test according to the data distribution-normal or nonnormal, respectively. The χ 2 test was used to compare categorical variables between groups. Correlations between 2 parameters were examined using a linear regression analysis. Multivariate logistic regression was used to estimate the association between cholesterol uptake capacity and CAD recurrence after adjustment for sex, age, current smoking, systolic blood pressure, hemoglobin (Hb) A 1c level, and the concentrations of triglyceride (TG), LDL-C, and HDL-C. Odds ratios are reported for a 1-SD change in continuous variables.
We also assessed the category-free net reclassification improvement (NRI) and integrated discrimination improvement (IDI) to investigate whether coassessment of uptake capacity using the established coronary risk factors would provide a more effective CAD risk stratification, as suggested by Pencina et al. (18) . P values <0.05 in a 2-tailed analysis were considered significant. Statistical analyses were performed using StatFlex 6.0 (Artech) and STATA 13 (Stata Corp.).
RESULTS

Development of a cell-free HDL functional assay
To establish the cell-free HDL functional assay, we invented the following assay scheme for measuring cholesterol uptake capacity. (i) HDL was incubated with fluorescently labeled cholesterol and (ii) captured by an apoA1-specific antibody coated onto the wells of a microplate. (iii) The cholesterol uptake capacity was evaluated by measuring the fluorescence intensity of the labeled cholesterol incorporated into HDL (Fig. 1) .
We initially sought to use an antibody with a minimal recognition bias between oxidatively modified and nonoxidized forms of apoA1. However, every commercially available antibody we tried showed a significant recognition bias for apoA1 in apoBdepleted serum samples (Fig. 3A in the online Data Supplement). We finally chose 1 antibody based on its ability to bind to both apoA1 in apoB-depleted serum and recombinant apoA1 (data not shown). Using epitope mapping, we found that the antibodyrecognition site of apoA1 contains several amino acids that are known targets of oxidative modification, and we speculated that the antibody binds to oxidized apoA1 with higher affinity than it does to nonoxidized apoA1, as reported previously (19) . To minimize this recognition bias, we examined the effects of H 2 O 2 -induced oxidation of apoA1 on the interaction between the antibody and apoA1 in apoB-depleted serum. As expected, treatment with 1 mol/L H 2 O 2 equalized the binding affinity between the 2 forms (Fig. 3, A and B, in the online Data Supplement). In addition, the same oxidation treatment did not affect the incorporation of BODIPY-cholesterol into HDL (Fig. 3C in the online Data Supplement). Therefore, we oxidized the HDL samples before capturing them with the antiapoA1 antibody, as described in Materials and Methods in the online Data Supplement.
Construction and performance evaluation of the cholesterol uptake assay
We examined the analytical performance of the cholesterol uptake assay and apoA1 ELISA. We assessed the specificity of the apoA1-capture antibody and confirmed that the antibody bound specifically to apoA1 and not to other HDL-containing apolipoproteins, such as apoA2 or apoE (Fig. 4 , A and B, in the online Data Supplement). Next, we evaluated the assay linearity by serially diluting apoB-depleted serum extracted from pooled serum from healthy individuals. A linear regression analysis gave the relationship r 2 > 0.99, and the curve was linear over the range of 0 -100 ng/mL of apoA1 ( Fig. 2A) . The linearity of the captured apoA1 concentration was also confirmed (Fig. 2B) . The within-run precision of the cholesterol uptake assay was assessed by measuring the concentration of apoB-depleted serum, and the CVs ranged from 0.3% to 7.0% (n = 4). We also found that the fluorescence intensity of the labeled cholesterol in HDL increased in a time-dependent manner (Fig.  2C) . These results suggest that the assay system has a high accuracy and robustness over a wide range of measured values.
Steroid structure of BODIPY-cholesterol is essential for its incorporation into HDL
BODIPY-cholesterol is composed of the steroid structure of cholesterol and the BODIPY moiety (Fig. 3A) . To confirm that the incorporation of BODIPY-cholesterol into HDL depends on its steroid structure, and not on the BODIPY moiety, we performed a competition assay using unlabeled cholesterol. As indicated in Fig. 3B , incorporation of the labeled cholesterol into HDL was suppressed by the addition of cholesterol in a concentration-dependent manner. Next, we examined whether the BODIPY moiety could be incorporated into HDL and found that incubation of the BODIPY label with HDL produced no fluorescent signal (Fig.  3C ). In addition, we confirmed the presence of a good correlation between the use of 3 H-cholesterol and BODIPY-cholesterol in the cholesterol uptake assay, indicating that the bulky BODIPY group had little effect on the behavior of cholesterol (Fig. 5 in the online Data Supplement). Therefore, we concluded that the steroid structure of BODIPY-cholesterol is necessary for its incorporation into HDL and that this labeled cholesterol has characteristics that are suitable for the evaluation of the cholesterol uptake capacity of HDL.
Cholesterol uptake capacity reflects the oxidative inactivation of HDL
In vitro oxidation of HDL impairs their ability to promote cholesterol efflux from macrophages (20, 21) . Huang et al. (21) observed that oxidized apoA1 recovered from human atheroma or plasma is lipid poor and loses its association with HDL particles. Therefore, we speculated that the MPOmediated oxidation of apoA1 in HDL impairs its ability to interact with lipids, including cholesterol. We examined whether the cholesterol uptake assay could be used to evaluate the inhibitory effects (A), The cholesterol uptake capacity of apoB-depleted serum, dependent on apoA1 concentration, was measured in the presence of 5 μmol/L BODIPY-labeled cholesterol. An anti-apoA1 monoclonal antibody (clone 1C5, black circle) or normal mouse IgG (white circle) was used as a capture antibody. ApoB-depleted serum was extracted from the pooled serum of multiple healthy donors. (B), The amounts of captured apoA1 in apoB-depleted serum were quantified using the detection antiserum. (C), The uptake capacity according to the incubation time for cholesterol uptake of apoB-depleted serum was measured for 5 μmol/L BODIPY-cholesterol and 100 ng/mL apoA1 in apoB-depleted serum. FI, fluorescence intensity; LI, luminescence intensity; a.u., arbitrary units. The values represent the average of quadruplicate (A and B) or triplicate (C) determinations; the error bars indicate 1 SD. of the MPO-mediated oxidation of apoA1 on HDL functionality. First, we exposed apoB-depleted serum or recombinant apoA1 to the MPO-H 2 O 2 -nitrite system and confirmed their oxidized forms with an anti-nitrotyrosine antibody (Fig. 4A) . Then, we observed that the oxidization of apoB-depleted serum decreased their efflux capacity in J774 macrophages (Fig. 4B) . We also found that the uptake capacity of apoB-depleted serum was suppressed by MPO-induced oxidation (Fig. 4C) . Because the MPO-induced oxidation of apoA1 is site specific and depends on its direct interaction with apoA1 (20, 22) , the site specificity of the oxidation is considered critical for the inhibition of cholesterol uptake capacity and might explain why H 2 O 2 treatment in the absence of MPO did not yield such negative effects on cholesterol uptake capacity (Fig. 3C in the online Data Supplement). These findings indicate that the oxidation of HDL impairs its cholesterol-acceptor function and that the cholesterol uptake assay may be used to evaluate the oxidation-induced inactivation of HDL.
ARTICLES
Cholesterol uptake capacity correlates with efflux capacity
Recent studies have demonstrated a significant association between efflux capacity and the risk of atherosclerosis and cardiovascular disease (CVD) (11, 12) . However, cell culture and time-consuming procedures are required for the measurement of efflux capacity. The objective of this investigation was to develop a cell-free and high-throughput assay system to provide another option for evaluating HDL functionality in reverse cholesterol ............................................................................................................ transport. Therefore, we examined the relationship between cholesterol uptake capacity and efflux capacity of apoB-depleted serum from human serum samples (n = 30). Because we found a good linear relationship between cholesterol uptake capacity and the concentration of recombinant apoA1, which showed a similar time dependence to that of HDL (Fig. 6 in the online Data Supplement), the recombinant apoA1 was used as a calibrator and standardized uptake capacity hereafter to correct for interplate variations, as described in Materials and Methods. The between-run precision of quality control sample was 9.6% (n = 3). Fig. 5A shows that there was a significant correlation between BODIPY-cholesterol uptake and efflux from J774 cells in the apoB-depleted serum samples (r 2 = 0.47, P < 0.001). Conversely, neither uptake nor efflux capacity showed a relationship with the amount of apoA1 in apoB-depleted serum (Fig. 5, B and C) . These findings suggest that cholesterol uptake capacity can be used as a functional index for HDL as well as efflux capacity.
Cholesterol uptake capacity is associated with the risk of CAD recurrence
We investigated the role of cholesterol uptake capacity in the risk stratification of patients with CAD. The clinical characteristics of the participants ( Table 1 in the online Data Supplement) showed that 24% of 230 sequential consenting subjects who had previously undergone successful revascularization required revascularization because of recurrent coronary lesions. We failed to observe a relationship between the recurrence of coronary lesions and cholesterol uptake capacity (Fig. 6A) . However, even after optimal lowering of LDL-C concentration, a substantial residual cardiovascular risk remains in patients with CAD (23). Therefore, next we examined the association between cholesterol uptake capacity and CAD recurrence in patients who had achieved an LDL-C goal of <100 mg/dL (24) (n = 156) ( Table 2 in the online Data Supplement). The recurrence of coronary lesions was inversely associated with cholesterol uptake capacity (Fig. 6B) . A multivariate logistic analysis adjusted for age, sex, smoking history, Hb A 1c level, blood pressure, and concentration of TG, LDL-C, and HDL-C in the serum showed that cholesterol uptake capacity was independently associated with the prevalence of coronary lesions (Fig. 6C) . In contrast, whereas there were no significant relationships between uptake capacity and the serum concentration of HDL-C or apoA1 (Fig. 7,  A and B, in the online Data Supplement), the serum HDL-C and apoA1 concentrations were inversely associated with the recurrence of coronary lesions ( Tables 1 and 2 in the online Data Supplement). However, neither of these factors remained significant in the multivariate logistic analysis in patients with optimal control of LDL-C (Fig. 7C in the online Data Supplement). We investigated whether the coassessment of cholesterol uptake capacity improves the risk stratification in these patients using the NRI and IDI classifications. The NRI for the detection of the risk of CAD recurrence by cholesterol uptake capacity increased significantly after the addition of cholesterol uptake capacity to serum HDL-C levels (60.2%, P = 0.002). The IDI after the addition of uptake capacity to the established risk factors (age, sex, smoking history, Hb A 1c level, blood pressure, and concentration of TG, LDL-C, and HDL-C in the serum) also increased significantly (7.7%, P = 0.006). Taken together, these data suggest that a higher cholesterol uptake capacity is associated with a decreased risk of CAD recurrence, especially in patients with optimal control of The association between cholesterol uptake capacity and efflux capacity (A), cholesterol uptake capacity and apoA1 in apoB-depleted serum (B), and cholesterol efflux capacity and apoA1 in apoB-depleted serum (C) were analyzed. The cholesterol uptake capacity and efflux capacity of apoB-depleted serum samples were measured as described in Materials and Methods in the online Data Supplement. apoB-depleted serum from 30 individuals was evaluated. The efflux capacity was divided by the amount of apoA1 in apoB-depleted serum because the uptake capacity was measured at a constant level of apoA1 in apoB-depleted serum (efflux capacity/apoB-depleted serum apoA1). The values represent single determinations (apoB-depleted serum apoA1) or the average of duplicate determinations (uptake capacity and efflux capacity/apoBdepleted serum apoA1).
New Measure of HDL Functionality and CVD Risk 
DISCUSSION
The development of a cell-free assay for evaluating HDL functionality may lead to new diagnostic approaches for studying and treating atherosclerosis and CVD. In this study, we invented a plate assay system to assess the capacity of HDL to uptake cholesterol without using radioisotopes or cells. Our data showed that cholesterol uptake capacity was associated with the risk of CAD recurrence. Among the conventional risk factors and cholesterol uptake capacity, only cholesterol uptake capacity remained significant in the multivariable analysis of samples from patients with a well-controlled LDL-C concentration. Thus, we propose that the cholesterol uptake capacity is a new diagnostic concept Box-and-whisker plots of cholesterol uptake capacity in all patients (n = 230; A) and in patients with an LDL-C concentration <100 mg/dL (n = 156; B) stratified according to the presence or absence of recurrence of coronary lesions. Box-and-whisker plots indicate 5th percentile, 25th percentile, 50th percentile, 75th percentile, and 95th percentile. The Mann-Whitney U test was used to calculate P values. (C), Odds ratios (symbols) and 95% CI (lines) for the requirement for repeat revascularization in patients who achieved an LDL-C goal of <100 mg/dL (n = 143). The odds ratios for continuous variables were for a 1-SD increase.
that may be useful for evaluating HDL functionality and the risk of CVD.
Recent studies have shown that the ability of HDL to promote cholesterol efflux from macrophages modulates the severity of atherosclerosis (11, 25, 26) . In humans with similar HDL-C concentrations, a higher capacity to remove cholesterol from macrophages is attributed mainly to a higher ATP-binding cassette subfamily A member 1 (ABCA1)-mediated efflux (27) . The initial interaction between apoA1 and ABCA1 is an essential step in cholesterol efflux (28) . However, in this study, we found a significant correlation between cholesterol efflux capacity and uptake capacity, although the cholesterol uptake assay was a cell-free, ABCA1-independent system. This observation suggests that, in addition to the interaction between apoA1 and ABCA1, the storage capacity of HDL for accepting cholesterol is an important determinant of the efficiency of cholesterol efflux from macrophages. On the other hand, as the efflux capacity depends not only on HDL properties, but also on the condition of cells, the uptake capacity seems likely to have an advantage from a perspective of reproducibility. Further trials are required to compare the usefulness of the 2 methods, the cellbased and cell-free HDL functional assays, for coronary risk stratification.
We have recently reported an inverse relationship between serum MPO level and cholesterol efflux capacity (29) . Some reports have shown that MPO-induced oxidation of several specific amino acids in apoA1 decreases the efflux capacity by impairing the interaction between apoA1 and ABCA1 (20, 21, 28) . In the present study, we found that the cholesterol uptake capacity was suppressed by the MPO-mediated oxidation of apoBdepleted serum or recombinant apoA1 protein.
Because the apoA1-ABCA1 interaction step is not involved in the assessment of uptake capacity, a structural change in apoA1 induced by oxidation might also affect its holding capacity for lipid molecules, including cholesterol (19, 21) . Moreover, we speculate that the uptake capacity assay may also reflect changes in the activity and/or composition of other HDL-containing proteins and lipids. We have recently reported that eicosapentaenoic acid, a polyunsaturated fatty acid, is efficiently incorporated into HDL particles and improves HDL functionality (30) . Our new assay system can, theoretically, reflect the absolute HDL functional level based on whole components of the lipoprotein. However, further studies are needed to confirm this hypothesis.
Li et al. (31) recently reported that cholesterol efflux to apoB-depleted serum was paradoxically associated with an increased prospective risk of CVD. A plausible reason for this discrepancy between their findings (31) and other reports (11, 25, 26) is that apoB-depleted serum contains not only HDL and apoA1 but also other components, such as albumin, that can accept the cholesterol that is released from macrophages. In this regard, we consider that the application of the anti-apoA1 antibody in the present assay system provides an advantage, by allowing a more specific evaluation of HDL functionality.
In the present study, we found that cholesterol uptake capacity was inversely associated with the recurrence rate of coronary lesion after revascularization in patients with optimal control of LDL-C concentration. The cholesterol uptake capacity also remained statistically significant after multivariate analysis, whereas neither serum HDL-C nor apoA1 concentration, which are conventional indices of the amount of HDL, showed such a relationship. This finding suggests that the quantity of HDL alone is insufficient for residual risk assessment after optimal control of LDL-C. We also demonstrated that the incorporation of cholesterol uptake capacity into a fully adjusted model (including HDL-C concentration) significantly improved the discrimination and reclassification of CAD risk stratification. Conversely, cholesterol uptake capacity was independently associated with CAD recurrence only after the exclusion of participants with an LDL-C concentration ≥100 mg/dL. This finding implies that the ability of HDL to accept cholesterol from peripheral tissues affects CVD risk more prominently when the cholesterol accumulation caused by LDL has a limited effect on the pathogenesis of atherosclerosis. However, as the present cross-sectional study was exploratory in purpose, a prospective validation study is required to investigate whether poor cholesterol uptake capacity could really be a residual cardiovascular risk in patients with optimal LDL-C control. We and other groups have shown that several types of statins and fibrates increase the amount of functional HDL (32) (33) (34) . It has also been reported that exercise and diet therapies increase cholesterol efflux capacity (35, 36) . Thus, cholesterol uptake capacity may be useful as a monitoring tool for assessing the efficacy of these treatments and therapies. In the meantime, a more efficient enhancement of the atheroprotective functions of HDL may decrease the risk of atherosclerosis and CVD, although it has been difficult to develop therapeutic drugs with the expected effects. We consider that this can be explained in part by the lack of a convenient assay system to evaluate HDL functionality without complicated or time-consuming procedures. In this respect, our cholesterol uptake assay provides a concise, accurate, and robust system for high-throughput analysis at low cost without the need for radiolabels and cultured cells.
In conclusion, the present study suggests that the measurement of the cholesterol uptake capacity of HDL in the circulation may provide a means of assessing the anti-atherosclerotic functions of HDL and that this cholesterol uptake assay may provide a reliable new diagnostic index for the prediction of CVD risk and the monitoring of treatment efficacy.
